As a 40-year-old who lives with cystic fibrosis (CF), Zachary Schulz, PhD, EdS, MPH, is said to be among the reputed “last generation” of patients — those born before the advent of drugs that target ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

The FDA has expanded indications for two targeted combination treatments, Alyftrek and Trikafta, that will now benefit more ...

This week, Bobbi Conner talks with MUSC's Dr. Christina Mingora about the impact of recent advances in treating cystic ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated disease that differs from person to person. An autosomal recessive disorder ...

Maren Denison, third-year student at the University of Iowa, was in sixth grade when she found out her lung function had dropped to 60 percent as half of her lung had collapsed and was scarred shut.

Breathing disorders are common in the U.S. with conditions like COPD affecting some 7% of the population and asthma affecting another 10%. Digestive conditions like GERD, acid reflux, Celiac disease ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life, presumably even in ...

The desire to have children represents one of the most fundamental human experiences, yet for people living with cystic fibrosis, the path to parenthood can feel uncertain and complex. You might ...

Protein clustering mechanism on the cell membrane presents a new therapeutic target for cystic fibrosis. A new study from The Hospital for Sick Children (SickKids) reveals the process underlying ...